Adverse events with everolimus in BOLERO-2

Affiliations

¹ Department of Oncology, Multidisciplinary Breast Center, University Hospitals Leuven, KULeuven (University of Leuven), Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.
² Department of Oncology, Multidisciplinary Breast Center, University Hospitals Leuven, KULeuven (University of Leuven), Leuven, Belgium.

Free article

Comment

P Neven et al. Ann Oncol. 2014 Sep.

Free article

. 2014 Sep;25(9):1861.

doi: 10.1093/annonc/mdu195. Epub 2014 May 29.

¹ Department of Oncology, Multidisciplinary Breast Center, University Hospitals Leuven, KULeuven (University of Leuven), Leuven, Belgium. Electronic address: patrick.neven@uzleuven.be.
² Department of Oncology, Multidisciplinary Breast Center, University Hospitals Leuven, KULeuven (University of Leuven), Leuven, Belgium.

No abstract available

Comment on

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hashimy M, Taran T, Burris HA 3rd. Rugo HS, et al. Ann Oncol. 2014 Apr;25(4):808-815. doi: 10.1093/annonc/mdu009. Epub 2014 Mar 10. Ann Oncol. 2014. PMID: 24615500 Free PMC article. Clinical Trial.